Vensica Medical secures $11 million in funding to trial overactive bladder treatment
Vensica Medical secures $11 million in funding to trial overactive bladder treatment
The company was established in the incubator program of The Trendlines Group and The Israel Innovation Authority.
Urology therapeutics company Vensica Medical has raised $11 million to fund its upcoming Phase 2 clinical trials across the United States and Europe. The trials will seek to treat overactive bladder (OAB) using botulinum toxin A (Xeomin) delivered through a proprietary, needle-free device.
The investment round was led by Israel Biotech Fund (IBF), alongside strategic partners Merz, a global player in neurotoxins, and Laborie, a urology medical device company. To date, the company has raised a total of $30 million since its founding in 2014 by Avner Geva and The Trendlines Group.
“We are thrilled to have the support of leading investors and partners who share our vision of transforming overactive bladder treatment,” said Geva, who serves as the company’s CEO. “This funding will allow us to push forward with Phase 2 trials and move one step closer to bringing this innovative therapy to the patients who need it.”
Vensica’s technology uses a needle-free drug delivery system that administers the medicine directly to the bladder wall. It is expected that this approach will offer patients a less invasive, more comfortable treatment option compared to traditional injections and potentially alter the standard of care for OAB. Vensica’s needle-free drug delivery system aims to be a urology treatment platform for the treatment of additional bladder indications.
As part of its strategic partnership with Merz, the company, which has a total of five employees, has secured exclusive rights to Xeomin in needleless therapeutic application in several urologic indications and will benefit from clinical development support.
